Genzyme Puts Up $22M To Settle FCA Claims
The settlement will resolve claims in a pair of whistleblower lawsuits brought by former Genzyme employees and a doctor. According to the U.S. Department of Justice, Genzyme sales representatives marketed Seprafilm for unapproved surgical uses that were not reimbursable under federal health care programs.
“There will be consequences when medical device companies...
To view the full article, register now.